STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib

Yan Ru Deng, Hong Di Ma, Koichi Tsuneyama, Wei Yang, Yin Hu Wang, Fang Ting Lu, Cheng Hai Liu, Ping Liu, Xiaosong He, Anna Mae Diehl, M. Eric Gershwin, Zhe Xiong Lian

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


There have been major advances in defining the immunological events associated with fibrosis in various chronic liver diseases. We have taken advantage of this data to focus on the mechanisms of action of a unique multi-kinase inhibitor, coined sorafenib, on CCl4-induced murine liver fibrosis, including the effects of this agent in models of both acute and chronic CCl4-mediated pathology. Importantly, sorafenib significantly attenuated chronic liver injury and fibrosis, including reduction in liver inflammation and histopathology as well as decreased expression of liver fibrosis-related genes, including α-smooth muscle actin, collagen, matrix metalloproteinases and the tissue inhibitor of metalloproteinase-1. Furthermore, sorafenib treatment resulted in translocation of cytoplasmic STAT3 to the nucleus in its active form. Based on this observation, we used hepatocyte-specific STAT3 knockout (STAT3Hep-/-) mice to demonstrate that hepatic STAT3 was critical for sorafenib-mediated protection against liver fibrosis, and that the upregulation of STAT3 phosphorylation was dependent on Kupffer cell-derived IL-6. In conclusion, these data reflect the clinical potential of the multi-kinase inhibitor sorafenib for the prevention of fibrosis as well as the treatment of established liver fibrosis and illustrate the immunological mechanisms that underlie the protective effects of sorafenib.

Original languageEnglish (US)
Pages (from-to)25-34
Number of pages10
JournalJournal of Autoimmunity
StatePublished - Oct 2013


  • IL-6
  • Kupffer cell
  • Liver fibrosis
  • Sorafenib
  • STAT3

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib'. Together they form a unique fingerprint.

Cite this